BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Mankind Pharma Sells Mahananda to Chalet Hotels for Rs 530 Crore

Synopsis:

Mankind Pharma approved the sale of its subsidiary, Mahananda Spa, to Chalet Hotels at an enterprise value of Rs 530 crore. The company will use the proceeds to reduce debt. Mankind Pharma share price is down 13% this year but gained 13% over the past year.


Mankind Pharma, India’s fourth-largest pharmaceutical company by domestic revenue, has approved the sale of its entire stake in Mahananda Spa to Chalet Hotels. The deal, valued at Rs 530 crore, is part of the company’s strategy to monetise non-core assets and reduce outstanding debt. The transaction is expected to be completed by February 28, 2025.

Mahananda Spa reported a turnover of Rs 74.33 crore in FY24 and had a net worth of Rs 401.35 crore. The sale proceeds will help Mankind Pharma strengthen its balance sheet as it continues to focus on core business expansion.

Also read: Lupin Gets U.S. FDA Approval for Ipratropium Bromide Nasal Spray

MANKIND PHARMA LIMITED

Trade

2465.3-91.59 (-3.58 %)

Updated - 30 April 2025
2584.80day high
DAY HIGH
2425.60day low
DAY LOW
734527
VOLUME (BSE)

Key Takeaways

  • Transaction Value: Rs 530 crore enterprise value for Mahananda Spa.

  • Debt Reduction: Sale proceeds to be utilised for partial debt repayment.

  • Financials of Mahananda Spa: Turnover of Rs 74.33 crore in FY24, net worth of Rs 401.35 crore.

  • Expected Closure: The transaction will be completed by February 28, 2025.

  • Strategic Focus: Mankind Pharma is streamlining operations to focus on core business growth.

Also read: Shriram Properties Signs JDA for Koyambedu Project Worth ₹350-400 Crore

Mankind Pharma’s Recent Developments and Financial Performance

In October 2024, Mankind Pharma completed the acquisition of Bharat Serums and Vaccines (BSV) for Rs 13,768 crore, strengthening its position in women’s health and fertility drugs. This acquisition also expanded its presence in the critical care segment.

The company delivered a strong Q2FY25, driven by demand for chronic medications for diabetes and cardiovascular conditions. However, its domestic formulations business has been under pressure due to slower growth in acute therapies, which contribute two-thirds of its revenue.

Mankind Pharma share price has declined by 13% this year but gained 13% over the past 12 months.

Mahananda Spa Transaction Overview

Parameter

Details

Buyer

Chalet Hotels

Seller

Mankind Pharma

Enterprise Value

Rs 530 crore

FY24 Turnover

Rs 74.33 crore

Net Worth

Rs 401.35 crore

Deal Closure Date

February 28, 2025

Mankind Pharma’s decision to divest Mahananda Spa aligns with its strategy to optimise financial resources and strengthen its market position. Investors are closely monitoring Mankind Pharma share price amid the company’s ongoing structural shifts.

Also read: RVNL Wins South Western Railway Project Worth ₹335.4 Crore

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text